CHE
Chemed Corporation
CHE has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over CHE overall, supported by stronger fundamentals and stronger modeled upside.
CHE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
CHE's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CHE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $550 | — |
| Cheap | 24x | $500 | -9.2% |
| Current | 26x | $550 | — |
| Fair | 29x | $602 | +9.5% |
| Expensive | 34x | $710 | +29% |
Historical ranges are pointers, not guarantees.
CHE has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CHE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CHE, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CHE on the outlook, with more favorable profitability expectations.
CHE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $27.06 | +30% |
| Q3 2026 | $20.87 | +10% |
| Q2 2026 | $19.88 | +2.3% |
| Q1 2026 | $18.32 | -11% |
| Q4 2025 | $18.34 | -7.8% |
| Q3 2025 | $18.89 | -4.6% |
| Q2 2025 | $19.43 | -1.5% |
| Q1 2025 | $20.51 | +10% |
| Q4 2024 | $19.89 | +11% |
CHE earned $20.87 per share over the past year, up 10% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CHE on earnings, with more consistent year-over-year improvement.
CHE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $690.9M | +11% |
| Q2 2026 | $673.3M | +8.8% |
| Q1 2026 | $657.5M | +1.6% |
| Q4 2025 | $639.3M | -0.1% |
| Q3 2025 | $624.9M | +3.1% |
| Q2 2025 | $618.8M | +3.8% |
| Q1 2025 | $646.9M | +9.8% |
| Q4 2024 | $640M | +9.2% |
CHE's revenue is growing: $691M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +2 points |
| Q2 2026 | 13% | +2.3 points |
| Q1 2026 | 13% | -1.8 points |
| Q4 2025 | 16% | -2 points |
| Q3 2025 | 12% | -3.2 points |
| Q2 2025 | 11% | -3.8 points |
| Q1 2025 | 15% | +2.4 points |
| Q4 2024 | 18% | -1.2 points |
CHE's operating margin was 14% last quarter, up 2 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CHE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CHE on profitability, with a higher operating margin.
CHE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $37.9M | -43% |
| Q2 2026 | $69.3M | -44% |
| Q1 2026 | $71.1M | +265% |
| Q4 2025 | $117.2M | -23% |
| Q3 2025 | $65.9M | -14% |
| Q2 2025 | $122.8M | +85% |
| Q1 2025 | $19.5M | -73% |
| Q4 2024 | $152.2M | +57% |
CHE's free cash flow has been positive every quarter for seven years: $295M over the past year, down 18% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CHE on cash flow, with more consistent year-over-year improvement.
CHE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -64K shares |
| 1 year | -8.8% | -1.3M shares |
| 3 years | -14% | -2.1M shares |
| 5 years | -17% | -2.7M shares |
| Available history | -21% | -3.4M shares |
CHE has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $62.5M |
| Q2 2026 | $97.5M |
| Q1 2026 | $190M |
| Q4 2025 | $174.6M |
| Q3 2025 | $180.8M |
| Q2 2025 | $42.9M |
| Q1 2025 | $33.2M |
| Q4 2024 | $209.3M |
CHE spent $525M buying back its own shares over the past year, up 13% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CHE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
CHE has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CHE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 65.1 | Neutral |
CHE's weekly RSI is 66 (neutral) and its Stochastic is 65 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CHE PE vs Healthcare Sector
| Metric | CHE | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 2% above |
| PE % | 32 | 29 | 3 pts above |
CHE has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CHE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $519.7 | 5.9% above |
| 20 week MA | $518.9 | 6% above |
| 50 week MA | $462.7 | 19% above |
| 100 week MA | $488.0 | 13% above |
| 200 week MA | $523.0 | 5.2% above |
CHE has climbed back above all five of its weekly moving averages, and it's now 5.2% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CHE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $438.7 | $536.7 | +22% |
| 2021 | $536.7 | $525.3 | -2.1% |
| 2022 | $525.3 | $516.2 | -1.7% |
| 2023 | $516.2 | $584.8 | +13% |
| 2024 | $584.8 | $522.8 | -11% |
| 2025 | $522.8 | $432.2 | -17% |
| 2026 YTD | $432.2 | $550.2 | +27% |
CHE has finished lower in four of the last six years. It's up 27% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CHE on returns for 2026, with the stronger performance.